YOUR LENTIVIRUS
SPECIALIZED PARTNER
Lentiviral vector GMP CDMO
DEVELOPMENT AND MANUFACTURING
LENTIVIRAL VECTOR GMP CDMO
Our main aim is to adapt to your own requirements from a technical and timeline perspective
R&D
LENTIVIRAL VECTOR R&D
Our main aim is to implement a technology development strategy focused on providing a response to the main hurdles that currently exist within the gene therapy field
LATEST NEWS
04 June 2020
VIVEbiotech collaborates with Xyphos Biosciences for clinical development support of convertibleCAR-T™ cell therapy
21 February 2020
VIVEbiotech SL will coordinate the Advanced Therapies Group of the Spanish Bioindustry Association (AseBio)
27 January 2020
VIVEbiotech participates in Phacilitate Leaders World and World Stem Cell Summit 2020
07 January 2020
The Diario Vasco echoes the new investments in VIVEbiotech
CONTACT OUR EXPERTS FOR FURTHER DISCUSSION
